Gottfrid Sjodahl

Medicon Village
Lund, M 22381, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Re: Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. 2026;12:49-50.

Re: Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. 2026;12:49-50.

Journal: European urology focus

Published: January 15, 2026

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.

Journal: NPJ precision oncology

Published: January 09, 2026

Proceedings of the first international NMIBC consensus classification meeting.

Proceedings of the first international NMIBC consensus classification meeting.

Journal: Bladder cancer (Amsterdam, Netherlands)

Published: December 15, 2025

Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System.

Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: October 02, 2025

CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.

CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.

Journal: Scientific reports

Published: September 02, 2025

Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases.

Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases.

Journal: Experimental hematology & oncology

Published: April 02, 2025

Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer.

Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer.

Journal: ESMO open

Published: March 24, 2025

Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting.

Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting.

Journal: Frontiers in oncology

Published: January 07, 2025

Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer.

Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer.

Journal: Bladder cancer (Amsterdam, Netherlands)

Published: December 05, 2024

Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.

Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.

Journal: JCO precision oncology

Published: September 30, 2024

Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.

Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.

Journal: Nature reviews. Urology

Published: September 12, 2024

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.

Journal: Cells

Published: April 11, 2024

Showing 1-12 of 73

Last Updated: 09/26/2026